Based on this, the author formulated the UCMS-MC540-TF nanovaccine by mixing MC540 and mice CT26 tumor cell lysates and found that it was able to not only combine PDT with immunotherapy, but also achieve activation of anti-tumor immune response with the adjuvant effect of PDT-induced ICD and mesoporous silica. The gene discussed is TF; the disease is neoplasm.